Business Context and Reporting Period
This Form 8-K Current Report was filed by SELLAS Life Sciences Group, Inc. on November 6, 2019. The report details a corporate action regarding the Company's capital structure intended to maintain its listing status on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a structural amendment to the Company's Certificate of Incorporation.
Material Changes
- Reverse Stock Split: The Company effected a 1-for-50 reverse stock split of its common stock.
- Effective Date: The split became effective at 5:00 p.m. Eastern Time on November 7, 2019.
- Trading Resumption: Post-split trading commenced on The Nasdaq Capital Market on November 8, 2019.
- Share Consolidation: Every 50 pre-split shares were combined into one post-split share without changing the par value.
- Fractional Shares: No fractional shares were issued; instead, the transfer agent aggregated and sold fractional interests, distributing net proceeds in cash to affected stockholders.
- Identification: The post-split common stock was assigned a new CUSIP number (81642T 209).
Outlook, Risks, and Management Commentary
Purpose: The primary objective of the reverse stock split is to increase the per-share trading price to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
Approval: The action was unanimously approved by the Board of Directors and subsequently approved by stockholders at a special meeting held on September 10, 2019.
Risks/Contingencies: The filing notes that stockholders entitled to fractional shares will receive cash payments net of brokerage costs incurred by the transfer agent during the sale of aggregated fractional shares.
Key Facts for Investor Verification
- Verify the post-split share count and new CUSIP number (81642T 209) in brokerage accounts.
- Confirm the receipt of cash payments for any fractional shares resulting from the 1-for-50 consolidation.
- Monitor the stock price on November 8, 2019, to ensure it meets the $1.00 minimum bid price requirement for Nasdaq listing.
- Review the press release filed as Exhibit 99.1 for additional details on the transaction.